DWS ESG Biotech LC
DE0009769976
DWS ESG Biotech LC/ DE0009769976 /
NAV10/05/2024 |
Diferencia-4.7900 |
Tipo de beneficio |
Enfoque de la inversión |
Sociedad de fondos |
280.5500EUR |
-1.68% |
reinvestment |
Equity
Worldwide
|
DWS Investment GmbH ▶ |
Estrategia de inversión
The fund is actively managed. The fund is not managed in reference to a benchmark. The fund promotes environmental and social characteristics and is subject to the disclosure requirements of a financial product in accordance with article 8(1) of Regulation (EU) 2019/2088 on sustainability-related disclosures in the financial services sector. More ESG information is available in the sales prospectus and on the DWS website. The objective of the investment policy is to achieve sustained capital appreciation that exceeds the benchmark (No benchmark).
To achieve this, the fund invests mainly in equities of international companies whose revenues or earnings, as reported in the most recent annual report or other suitable documents of the company, were generated primarily from the biotechnology sector, or whose expenditure was primarily on this sector. Equities of issuers from the health care sector may also be added. When selecting the suitable investments, environmental and social aspects as well as the principles of corporate governance ("ESG standards") are of key importance for the implementation of the fund"s sustainable investment strategy.
Objetivo de inversión
The fund is actively managed. The fund is not managed in reference to a benchmark. The fund promotes environmental and social characteristics and is subject to the disclosure requirements of a financial product in accordance with article 8(1) of Regulation (EU) 2019/2088 on sustainability-related disclosures in the financial services sector. More ESG information is available in the sales prospectus and on the DWS website. The objective of the investment policy is to achieve sustained capital appreciation that exceeds the benchmark (No benchmark).
Datos maestros
Tipo de beneficio: |
reinvestment |
Categoría de fondos: |
Equity |
Región: |
Worldwide |
Sucursal: |
Sector Biotechnology |
Punto de referencia: |
- |
Inicio del año fiscal: |
01/10 |
Última distribución: |
02/01/2018 |
Banco depositario: |
State Street Bank International GmbH |
País de origen: |
Germany |
Permiso de distribución: |
Austria, Germany |
Gestor de fondo: |
Dr. Noushin Irani |
Volumen de fondo: |
364.61 millones
EUR
|
Fecha de fundación: |
16/08/1999 |
Enfoque de la inversión: |
- |
Condiciones
Recargo de emisión: |
5.00% |
Max. Comisión de administración: |
1.30% |
Inversión mínima: |
0.00 EUR |
Deposit fees: |
- |
Cargo por amortización: |
0.00% |
Prospecto simplificado: |
Descargar (Versión para imprimir) |
Sociedad de fondos
Fondos de empresa: |
DWS Investment GmbH |
Dirección: |
Mainzer Landstraße 11-17, 60329, Frankfurt am Main |
País: |
Germany |
Internet: |
www.dws.de
|
Activos
Stocks |
|
93.90% |
Money Market |
|
3.10% |
Cash |
|
3.00% |
Países
United States of America |
|
82.10% |
Netherlands |
|
4.10% |
Denmark |
|
3.20% |
Germany |
|
1.80% |
United Kingdom |
|
0.70% |
Ireland |
|
0.60% |
Virgin Islands (British) |
|
0.50% |
Canada |
|
0.40% |
Sweden |
|
0.30% |
Switzerland |
|
0.20% |
Otros |
|
6.10% |
Sucursales
Pharma/Biotechnology |
|
89.70% |
Pharma, production |
|
4.30% |
Otros |
|
6.00% |